recombinant activated factor viia and hemostasis in critical care a focus on trauma重组激活因子viia和止血急救护理关注的创伤.pdfVIP

Available online /supplements/9/S5/S37 Review Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma 1 2 3 4 Alicia M Mohr , John B Holcomb , Richard P Dutton and Jacques Duranteau 1Assistant Professor of Surgery, Department of Surgery, New Jersey Medical School, Newark, New Jersey, USA 2COL, MC, US Army, Chief, Trauma Division, Trauma Consultant for The Surgeon General Commander, US Army Institute of Surgical Research, Fort Sam Houston, Texas, USA 3Associate Professor of Anesthesiology, University of Maryland School of Medicine, Baltimore, Maryland, USA 4Professor, Departement d’Anesthesie-Reanimation, Hopital de Bicetre, Le Kremlin-Bicetre, France Corresponding author: Alicia M Mohr, mohr@ Published online: 7 October 2005 Critical Care 2005, 9(Suppl 5):S37-S42 (DOI 10.1186/cc3784) This article is online at /supplements/9/S5/S37 © 2005 BioMed Central Ltd Abstract of hypothermia, acidosis, and coagulopathy, then surgical In this article we describe the current use of recombinant activated control is less likely to be effective alone [9]. Coagulopathy in factor VII (rFVIIa; NovoSeven®) in trauma patients. Emphasis is trauma may also be due to traumatic brain injury, fat embolus placed on current uses as defined by key studies, efficacy data, syndrome, or pre-existing comorbidities requiring oral anti- and safety data. Most published studies in trauma patients are coagulation. Attempts to minimize transfusion of blood and retrospective cas